RE:MUSKOKA RetreatThe only thing that may move this in the short term is positive news on the FDA Type C meeting. That should come in four weeks or less and may be followed shortly thereafter by expansion of current US market agreement. If in optimistic scenario we add to that with some new material QAPs agreement(s) and record fourth quarter/ FY2023 results it could be an interesting calendar year end. Fingers crossed!!